sub:assertion {
  d:DB08913 v:identifier "DB08913" ;
    v:namespace "drugbank" ;
    v:uri "http://bio2rdf.org/drugbank:DB08913" ;
    v:x-identifiers.org <http://identifiers.org/drugbank/DB08913> ;
    dv:drugbank-id "DB05677" , "DB08913" ;
    dv:x-cas <http://bio2rdf.org/cas:444811-40-9> ;
    dv:x-ndc <http://bio2rdf.org/ndc:50419-208-01> ;
    dv:x-wikipedia <http://bio2rdf.org/wikipedia:Radium-223_chloride> ;
    dct:description "Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first approved by the FDA in May 2013 and is currently marketed under the brand name Xofigo, which was formerly called Alpharadin. Xofigo is indicated in patients who have metastatic bone cancer that is symptomatic with no visceral metastases and patients who have prostate cancer that is castration resistant. The FDA label includes a warning that Radium Ra 223 Dichloride should not be used in women who are pregnant or may become pregnant due to the high risk of fetal harm."@en ;
    dct:identifier "drugbank:DB08913" ;
    dct:title "Radium Ra 223 Dichloride"@en ;
    a dv:Drug ;
    rdfs:label "Radium Ra 223 Dichloride [drugbank:DB08913]"@en ;
    rdfs:seeAlso <http://www.drugbank.ca/drugs/DB08913> , <http://www.drugs.com/xofigo.html> , <http://www.rxlist.com/xofigo-drug.htm> .
}